INTRAMURAL INSTITUTIONAL CERTIFICATION*

Institutional Certification for studies using data generated from cell lines created or clinical specimens collected BEFORE August 31, 2015, that HAVE CONSENT

Date: [MM/DD/YYYY]	
Name of GPA:	
Genomic Program Administrator(GPA)	
	lth (NIH), U.S. Department of Health and Human Services (HHS)
_	
RE: Institutional Certification of	
Submission of the Dataset from	original study name ¹] for
	[PROJECT TITLE FOR DATA TO BE SUBMITTED] ${ m to}$
an NIH-designated repository.	
T 4 N. 11 C CH 14 OH	
To the National Institutes of Health (NIF	H), U.S. Department of Health and Human Services (HHS):
	nated data repository is being made with Institutional approval from
	, along with appropriate institutional approvals from
collaborating sites, as listed here:	
[IF APPLICABLE, ENTER COLLABORATING SITE NAMES HERE A FILL OUT AVAILABLE ENTRIES AND FORM WILL THEN CREAT	AND CLICK "ADD TO LIST". IF MORE THAN FOUR (4) COLLABORATING SITES ARE INVOLVED, COMPLETELY TE ENTRIES FOR ADDITIONAL SITES]
COLLABORATING SITE NAME	LIST OF COLLABORATING SITES
Гће	hereby assures that submission of data from the study entitled
Γhe	
	to an NIH-designated data repository
	efined in the NIH Genomic Data Sharing (GDS) Policy (NIH Guide
Notice Number NOT-OD-14-124):	

- The data submission is consistent, as appropriate, with applicable national, tribal, and state laws and regulations as well as relevant institutional policies.
- Any limitations on the research use of the data, as expressed in the informed consent documents, are delineated in the table for Institutional Certification Data Use Limitations (DUL) in this document.
- The identities of research participants will not be disclosed to NIH-designated data repositories.
- An Institutional Review Board (IRB), and/or Privacy Board, and/or equivalent body, as applicable, has reviewed the investigator's proposal for data submission and assures that:
 - The protocol for the collection of genomic and phenotypic data is consistent with 45 CFR Part 46. (45 CFR Part 46. Protection of Human Subjects);
 - O Data submission and subsequent data sharing for research purposes are not inconsistent with the informed consent of study participants from whom the data were obtained;
 - Consideration was given to risks to individual participants and their families associated with data submitted to NIH-designated data repositories and subsequent sharing, including unrestricted access to genomic summary results;
 - o To the extent relevant and possible, consideration was given to risks to groups or populations associated with submitting data to NIH-designated data repositories and subsequent sharing, including unrestricted access to genomic summary results; and
 - The investigator's plan for de-identifying datasets is consistent with the standards outlined in the NIH Genomic Data Sharing (GDS) Policy (See section IV.C.1).

^{*} Certification must be provided for all sites contributing samples. If more than one site is contributing samples, the primary site may submit one Institutional Certification indicating that they are providing certification on behalf of all collaborating sites. Alternatively, each site providing samples may provide its own Institutional Certification.

Availability of Individual-Level Human Data

Controlled-access²

The individual-level data are to be made available through (check one)

Unrestricted acco	ess^3
If unrestricted account need to be comp	ess is marked, the data use limitations table on the following page(s) does pleted.
Is the individual-level,	human genomic data to be submitted funded in whole or in part by NIH?
YES	NO
is funded in whole of	our research involves the generation of individual-level, human genomic data and or in part by NIH, your research is automatically deemed to be issued a Certificate CoC). For more information, see the NIH Certificates of Confidentiality webpage.
Is the individual-level,	human genomic data to be submitted covered by a CoC?
YES	NO
Availability of Genomic Sur	mmary Results (GSR)
repositories through uni "sensitivities" related to from isolated geographi "sensitive" by In such cases, "controll designation should be p	summary results ⁴ (GSR) from most studies submitted to NIH-designated data restricted access. However, data from data sets considered to have particular individual privacy or potential for group harm (e.g., those with populations c regions, or with rare or potentially stigmatizing traits) may be designated as and public posting would be prohibited. ed access" should be checked below and a brief explanation for the sensitive provided. GSR from any such study will only be available through controlleding would be prohibited.
Controlled acces	
	as sensitive and "controlled access" is checked above, are the GSR covered
under (or have been is	
YES	NO
	nated as sensitive and available only via controlled access, they may be subject to Confidentiality Policy if there is at least a very small risk the individuals included in

the summary results may be re-identified.

Institutional Certification Data Use Limitations (DUL)

NIH expects the submitting institution(s) to select one of the three standard <u>Data Use Limitations</u> (DULs) for appropriate secondary use, or, if necessary, create a customized DUL. DULs are developed based on the original informed consent of the participant(s).

Data Use Limitations

General Research Use	GRU	Use of the data is limited only by the terms of the Data Use Certification: these data will be added to the dbGaP Collection.
Health/Medical/Biomedical	HMB	Use of the data is limited to health/medical/biomedical purposes, does not include the study of population origins or ancestry.
Disease-specific [list disease]	DS	Use of the data must be related to the specified disease.
Other		[ENTER CUSTOMIZED TEXT, IF APPLICABLE]

Additional modifiers to the standard DULs (e.g., not-for-profit use only) can be indicated, if appropriate. Use of the modifiers should have a basis in the informed consent from the participants or in special knowledge of the preferences of the original study population.

Data Use Limitation Modifiers (Optional)

IRB Approval Required	IRB	Requestor must provide documentation of local IRB approval.
Publication Required	PUB	Requestor agrees to make results of studies using the data available to the larger scientific community.
Collaboration Required	COL	Requestor must provide a letter of collaboration with the primary study investigator(s).
Not-for-profit Use Only	NPU	Use of the data is limited to not-for-profit organizations.
Methods	MDS	Use of the data includes methods development research (e.g., development and testing of software or algorithms).
Genetic Studies Only	GSO	Use of the data is limited to genetic studies only.

Using the tables above, please indicate in the table below the consent group(s) for each collaborating study site. Use one row per consent group.

Collaborating Site Name	Data Use Limitation	Data Use Limitation Modifiers (optional)						
Eg: Cold Cohort Study	Health/Medical/Biomedical		IRB 🗌	PUB 🗌	COL	NPU 🔲	MDS	GSO 🔲
Eg: Cold Cohort Study	Disease Specific Research [IRB	PUB	COL	NPU 🔀	MDS	GSO□
			IRB	PUB	COL	NPU	MDS	GSO
			IRB	PUB	COL	NPU	MDS	GSO
			IRB	PUB	COL	NPU	MDS	GSO
			IRB	PUB	COL	NPU	MDS	GSO

SIGNATURE PAGE FOR THIS INSTITUTIONAL CERTIFICATION

SUBMITTED AND AGREED TO BY:

Investigator:		
Name:	Title:	
Signature:		
Scientific Director/Designee:		
senior-level institutional staff (e.g., De	frivacy Board or equivalent body, and other relevan an, Vice-President/Provost for Research, Chief Scients in this certification and agree that the submission	ence
Name:	Title:	
Signature:	Date:	

Any false or misleading statements made, presented, or submitted to the Government, including any relevant omissions, under this Certification are subject to all applicable civil and criminal statutes including Federal statutes 31 U.S.C. §§3801-3812 (civil liability) and 18 U.S.C. §1001 (criminal liability including fine(s) and/or imprisonment).

REFERENCES

- 1. Original Study Name should reflect the name of the original IRB-approved study (e.g., cohort or case-control study, clinical trial) under which participants provided informed consent and biospecimens were collected (e.g., Nurses' Health Study, Framingham Heart Study).
- 2. Data made available for secondary research only after investigators have obtained approval from NIH to use the requested data for a particular project.
- 3. Data made publicly available to anyone.
- 4. For the purposes of the NIH Genomic Data Sharing (GDS) Policy, genomic summary results (GSR) are defined to include those provided by a study's investigator, if any, as well as summary statistics that may be computed by relevant NIH-designated data repository across all non-"sensitive" studies with data included in that repository. GSR include systematically computed statistics such as, but not limited to: 1) frequency information (e.g., genotype counts and frequencies, or allele counts and frequencies); and 2) association information (e.g., effect size estimates and standard errors, and p-values) (NIH Guide Notice NOT-OD-19-023).